

DLK
1

LIMPII. (31% identity, 74% similarity). We also identified additional repeating motifs, including aa 173-230 (SEQ ID NO. 2) (20% identity, 70% similarity). Human immunodeficiency virus type I (HIV-1) also contains a CLESH-1 motif and may be susceptible to binding/immobilization by CLESH-1 binding and modulation of any biological activity dependent on the availability of the HIV-1gp120 CLESH-1 motif.

IN THE CLAIMS

Please cancel claim 1 and withdrawn claims 4-31. Also, add new claims 32-45 as follows. (All the pending claims 2, 3 and 32-45 are shown for the Examiner's convenience):

- E1
D17
2. (Amended) A pharmaceutical composition comprising a protein which comprises a thrombospondin-binding motif of HRGP, in a pharmaceutically acceptable carrier, wherein the protein binds TSP-1 and thereby inhibits the antiangiogenic activity of TSP-1.
3. The pharmaceutical composition according to claim 2, wherein the composition is produced under GMP conditions or is of clinical grade, or both.
32. (New) The pharmaceutical composition according to claim 2, wherein the thrombospondin-binding motif of HRGP is a thrombospondin-binding motif of a mammalian HRGP.
33. (New) The pharmaceutical composition according to claim 32, wherein the mammalian HRGP is human HRGP.
34. (New) The pharmaceutical composition according to claim 2, wherein said protein is a mammalian HRGP.
35. (New) The pharmaceutical composition according to claim 34, wherein said mammalian HRGP is human HRGP.
36. (New) The pharmaceutical composition according to claim 2, wherein the thrombospondin-binding motif of HRGP is SEQ ID NO: 1.
- D18
- 504
E1

- Sub E
37. (New) The pharmaceutical composition according to claim 2, wherein the thrombospondin-binding motif of HRGP is SEQ ID NO: 2.
38. (New) The pharmaceutical composition according to claim 2, wherein the protein comprises the amino acid sequences of both SEQ ID NO:1 and SEQ ID NO: 2.
39. (New) The pharmaceutical composition according to claim 2, wherein the protein comprises one or more of the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.
- D8 W
40. (New) The pharmaceutical composition according to claim 39, wherein the protein comprises SEQ ID NO:9 and SEQ ID NO:4.
41. (New) The pharmaceutical composition according to claim 39, wherein the protein comprises SEQ ID NO:4 and SEQ ID NO:5.
42. (New) The pharmaceutical composition according to claim 39, wherein the protein comprises SEQ ID NO:3 and SEQ ID NO:5.
43. (New) The pharmaceutical composition according to claim 39, wherein the protein comprises SEQ ID NO:13 and SEQ ID NO:11.
44. (New) The pharmaceutical composition according to claim 39, wherein the protein comprises SEQ ID NO:9 and SEQ ID NO:8.
45. (New) The pharmaceutical composition according to claim 39, wherein the protein comprises SEQ ID NO:11 and SEQ ID NO:4.